TBX1 and chordoma: A subsequent phase I clinical trial added an anipox vector enhancer to the MVA vaccine to further enhance brachyury-specific T-cell responses in three patients with advanced chordoma, the result showed that the best response was SD according to RECIST, and the resulting immune response continued to increase [17].